PharmaPoint: Meningococcal Vaccines - UK Drug Forecast and Market Analysis to 2022
GlobalData has released its new Country report, “PharmaPoint: Meningococcal Vaccines - UK Drug Forecast and Market Analysis to 2022”. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofi’s Menactra and Novartis’ Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.
GlobalData predicts that relative patient share for the three MenC conjugate vaccines will shift due to changes being made to the UK MenC schedule (DOH, 2013b). Meningitec will lose sales due to its elimination from the single primary dose, with patient share expected to be made up by Menjugate and NeisVac-C.
Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in the UK from 2012-2022.
Analysis of the impact of key events as well the drivers and restraints affecting the UK Meningococcal Vaccines market.
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of drug performance
Obtain sales forecast for drugs from 2012-2022 in the UK
Sales for Meningococcal Vaccines in the UnitedKingdom
The United Kingdom meningococcal vaccinemarket was worth approximately $47.5 million in2012, with a projected negative compound annualgrowth rate (CAGR) of 0.1%, to reach a total of$47.2 million in 2022. These sales are drivenprimarily by the administration of MenC conjugatevaccines to infants and toddlers as part of thecountry’s recommended immunization schedule.
GlobalData expects that some of the mostimportant drivers of United Kingdom market growthover the next decade will be:
The entrance of serogroup B vaccines,particularly Novartis’ Bexsero, into themarketplace has the potential to drive growthin the UK meningococcal vaccines market.
Collaboration between vaccine manufacturersand patient-advocacy groups will increasepatient awareness and pressure policymakersto expand the meningococcal programGlobalData believes that notable barriers to growthof United Kingdom meningococcal vaccines marketwill include:
A cost-conscious government will oppose theexpansion of vaccine coverage beyond thosealready recommended for routine vaccination,capping market growth to within these narrowage segments. The declining incidence rates ofmeningococcal disease contribute to thisposition.